#ESMO26 | Anbenitamab + HB1801
我的理解正确吗？
55%的患者为HR阳性，但试验期间无人接受内分泌治疗！
这项试验始于2023年，对照组为THP。
鉴于内分泌治疗在HR+/HER2+转移性乳腺癌中已确立的作用，尤其是在维持治疗阶段，如果不考虑其被省略这一点，我们该如何解读这些结果？
这引发了对该试验设计及其研究结果对当代临床实践适用性的严重担忧。
266 浏览 · 2 赞 · 1 转发 · 3 回复
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgAnbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org- Yakup Ergün@dr_yakupergun
I could understand leaving ET to the treating physician’s discretion, as in DB09 and HER2CLIMB-05. However, not including ET in the protocol at all is an entirely different matter. I hope I’m wrong, but my interpretation of the paper is that patients did not receive ET. Moreover, I couldn’t find any statement in the paper indicating that they did.
- Dr Amol Akhade@SuyogCancer
@dr_yakupergun I agree . Endocrine therapy should be part of Treatment. But lots of trial did not have it mandatory. They leave it upto treating physicians to decide.
- Yakup Ergün@dr_yakupergun
@SuyogCancer
来源：Yakup Ergün · x.com